ABSTRACT NUMBER: ESOC2026A1268 PATIENTS WITH LARGER INFARCT CORES RANDOMIZED TO ARG-007 HAD BETTER FUNCTIONAL OUTCOMES: RESULTS FROM THE PHASE II ARG-007-002 SEANCON TRIAL
Davide Carone, David Blacker, Graeme Hankey, Meghan Thomas, George Harston · 2026
Read ABSTRACT NUMBER: ESOC2026A1268 PATIENTS WITH LARGER INFARCT CORES RANDOMIZED TO ARG-007 HAD BETTER FUNCTIONAL OUTCOMES: RESULTS FROM THE PHASE II ARG-007-002 SEANCON TRIAL by Davide Carone, David Blacker, Graeme Hankey, Meghan Thomas, George Harston (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13146304.txt.
Description
Davide Carone, David Blacker, Graeme Hankey, Meghan Thomas, and George Harston present a 2026 conference abstract on a stroke drug that seemed to help the worst-hit patients most. The trial tested a charged peptide, given by vein, in patients having clot removal for acute stroke. The main trial found the drug safe. This side analysis sorted patients by the size of the dead core on their first scans, read by imaging software.
Ninety of ninety-three patients had usable scans. By chance, the drug group started with larger cores. Modeling found the drug's edge grew with core size: lower early stroke scores and better three-month function than placebo. The authors pitch large-core patients as the group to target next.
Catalog record
| CREATOR | Davide Carone, David Blacker, Graeme Hankey, Meghan Thomas, George Harston |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |